GlassScriptPhysician profile
Matthew Douglas Ashmun
NPI 1912948225
$18,733.21
in general payments reported to CMS, 2019-2025
44 companies · $3,603 in 2025
The $3,603 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,021 · 2020: $1,643 · 2021: $2,781 · 2022: $2,960 · 2023: $2,685 · 2024: $3,042 · 2025: $3,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,307 · Education: $22.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,306.68 |
| Education | $22.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,817.69 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,486.10 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,773.74 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,567.31 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $792.56 | 2019-2025 | |
| Pfizer INC. | $654.76 | 2019-2025 | |
| Qol Medical, LLC | $620.74 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $596.64 | 2020-2025 | Linzess |
| Ferring Pharmaceuticals INC. | $465.83 | 2019-2024 | Rebyota, Cimzia, Clenpiq |
| Phathom Pharmaceuticals, INC. | $435.21 | 2023-2025 | Voquezna |
| Genzyme Corporation | $389.06 | 2022-2025 | |
| Celgene Corporation | $371.65 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $344.54 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $340.90 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $331.99 | 2019-2025 | Suflave, Sutab |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $328.76 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $311.88 | 2020-2025 | Ocaliva |
| Redhill Biopharma INC. | $250.68 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Nestle Healthcare Nutrition INC. | $242.88 | 2020-2023 | |
| Amgen INC. | $180.08 | 2020-2023 | Amjevita, Avsola |
| Organon LLC | $161.85 | 2023-2025 | Renflexis, Hadlima |
| Lilly USA, LLC | $134.63 | 2023-2025 | Omvoh, Zepbound |
| Evoke Pharma, INC. | $123.37 | 2023-2025 | Gimoti |
| Madrigal Pharmaceuticals | $109.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Ucb, INC. | $105.55 | 2019-2020 | |
| Celltrion USA INC. | $93.96 | 2024-2025 | Vegzelma, Zymfentra |
| Romark Laboratories, Lc | $81.12 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $79.48 | 2025 | Iqirvo |
| Medtronic, INC. | $68.39 | 2021-2023 | Gi Genius |
| Vivus LLC | $67.72 | 2022-2024 | Qsymia |
| Novo Nordisk INC | $64.92 | 2025 | Wegovy |
| Echosens North America, INC. | $61.89 | 2024-2025 | Fibroscan, Fibroscan |
| Allergan, INC. | $52.67 | 2019 | |
| Albireo Pharma, INC. | $42.75 | 2024 | Bylvay, Iqirvo |
| Enterra Medical, INC. | $25.31 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.53 | 2019-2020 | |
| Digestive Care, INC. | $19.68 | 2023 | Pertzye |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.54 | 2023 | Cyltezo |
| Dynavax Technologies Corporation | $16.75 | 2021 | |
| Alfasigma USA, INC. | $14.44 | 2020 | |
| Axonics, INC. | $13.93 | 2022 | |
| Lucid Diagnostics INC. | $13.56 | 2022 | |
| Endogastric Solutions, INC | $12.49 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ashmun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.